Clinical Trials Browser

Phase 1/2 × Terminated × Primary Myelofibrosis × Clear all

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

NCT00522990 2024-08-02

Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias

Phase 1/2 Terminated

48 enrolled

LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

NCT02440685 2023-06-07

A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors

Phase 1/2 Terminated

51 enrolled 18 charts

LymphoidMyeloidOther hematologic neoplasm

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, Mantle-Cell, Primary Myelofibrosis

NCT04866056 2022-12-01

Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.

Phase 1/2 Terminated

1 enrolled

Myeloid

Myelodysplastic Syndromes, Myeloproliferative Disorders, Primary Myelofibrosis

NCT02431260 2019-06-14

An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies

Phase 1/2 Terminated

69 enrolled 34 charts

BreastGastrointestinalLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Burkitt Lymphoma, Carcinoma, Non-Small-Cell Lung, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Colorectal Neoplasms, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Hematologic Neoplasms, Primary Myelofibrosis

Clinical Trials

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias

A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors

Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.

An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies